Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Appointment
- Honorary Senior Research Fellow
- Department of Targeted Intervention
- Div of Surgery & Interventional Sci
- Faculty of Medical Sciences
Biography
I obtained my BSc in Biochemistry at the University
of Manchester, shortly followed by a PhD with Dr M.Deonarain and a
biotechnology company called Photobiotics developing new drugs for Photodynamic
therapy. While writing my thesis I undertook a brief 6 month placement at ETH
Zurich in Switzerland under Prof. D.Neri to study antibody fragment
re-engineering. This was followed with 3 years as a postdoctoral research
associate at University College London with Prof. L.Lovat developing biomarker
targeted antibody based drug conjugates for photodynamic therapy in oesophageal
cancer.
Research Themes
See More
See LessResearch Summary
In my current project we want to use novel, non-invasive and inexpensive blood and urine tests to rationalise selection of patients with prostate cancer, this will improve the diagnosis and prognosis of patients with prostate cancer at an early stage. Reducing the amount of men who have to live with a ‘no mans land’ diagnosis i.e. somewhere between ‘unlikely to have’ and ‘certain to have’ cancer. It will also increase the amount of men who have access to MRI based diagnosis techniques – currently restricted due to NHS economics. We are trying to work in such a way that the ‘pathway’ we develop for the clinical evaluation of emerging fluidic markers in prostate cancer will translate quickly and directly into clinical practice. Trying to more efficiently connect academic discovery to actual patient benefit is very motivating.
